Waters Settles Last ABI/MDS Suit for $18.1M: Company Ready to Move On | GenomeWeb

Waters closed a painful chapter this week with the announcement of a final settlement of its patent disputes with Applied Biosystems and MDS, in which Waters agreed to pay $18.1 million to the companies, in addition to licensing fees, to settle outstanding suits in the UK, Canada, and Japan. In addition, the companies settled a countersuit that Waters had filed in the US alleging that ABI and MDS infringed on one of its electrospray technology patents, with ABI and MDS agreeing to pay licensing fees to Waters for use of that technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.